Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics of Vitamin D in Multiple Sclerosis and in Health

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Female~* Healthy or multiple sclerosis~* Aged 18 to 60~* Body mass index is between 18 kg/m2 and 30 kg/m2~* Screening 25-hydroxyvitamin D level ≤ 75 nmol/L (30 ng/mL)~* White race~* Non-Hispanic ethnicity~* Willing to use birth control during study~* Willing to not use tanning bed during study~If subject has multiple sclerosis:~* Relapsing-remitting MS, as defined by McDonald 2005 criteria~* Screening Expanded Disability Status Scale score ≤ 3.0~* Using no medication for MS, or taking Copaxone, (glatiramer acetate), interferons, or natalizumab~Exclusion Criteria:~* Pregnant or nursing~* Taking multivitamin \& unwilling to remain off it during study~* Taking cod liver oil \& unwilling to remain off it during study~* On a fat-restricted diet~* History of renal disease or nephrolithiasis (kidney stones)~* History of liver disease~* Taking thiazide diuretics~* History of hyperthyroidism~* History of infection with Mycobacterium species~* History of sarcoidosis~* History of cancer~* History of cardiac disease~* History of HIV~* History of gastrointestinal disorder~* Taking medications that interfere with gastrointestinal absorption~* Cigarette smoker in past month~* Use of illicit drugs in past month~* Use of steroids in past month~* History of hypercalcemia, and screening serum calcium ≤ 10 mg/dL (UCSF) or ≤ 10.7 mg/dL (Johns Hopkins)~* History of hypercalciuria~* Evidence of anemia (Hgb \<11.0 g/dL)~* History of other serious medical conditions~* Taking medications that involve the P450 system or may interact with vitamin D (digoxin, diltiazem, verapamil, cimetidine, heparin, or low-molecular weight heparin)~* Other concerns about safety from the perspective of the treating physician~If subject has MS:~-History of major heat sensitivity (leading to sun-avoidant behaviors)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Vitamin D3 (Type: EXPERIMENTAL): Both those with MS and healthy controls will be given vitamin D3 5000 IU/day by mouth for 90 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).